Clinical Trial: REal World Information on Cardiovascular Drug Management Patterns in Acute Coronary Syndrome paTients
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: REal World Information on Cardiovascular Drug Management Patterns in Acute Coronary Syndrome paTients
Brief Summary: RE-ACT is a national, multi-centre, observational, prospective, longitudinal cohort study which will include patients hospitalized for ACS within 24 hours of symptom onset and who have a final diagnosis of ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI). This study aims to describe the short-term (at the end of the first month after index event) antithrombotic management patterns in a "real-life" setting for patients hospitalized with an acute coronary syndrome.
Detailed Summary:
Sponsor: AstraZeneca
Current Primary Outcome: Short-term antithrombotic management patterns (AMPs) in a real-life setting for patients hospitalized with an ACS [ Time Frame: Baseline ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Variations in the acute clinical management strategies and AMPs. [ Time Frame: Baseline ]Descriptive statistics will be calculated for this outcome measure using frequency tables (n, frequency and percentage).
- Impact of the different AMPs on quality of life at discharge from hospital (using EuroQoL-5D). [ Time Frame: Baseline ]Descriptive statistics will be calculated for this outcome measure using frequency tables (n, mean, median, standard deviation, minimum and maximum)
- Impact of the different AMPs on quality of life at the end of the first month after discharge from the hospital (using EuroQoL-5D). [ Time Frame: At the end of the first month after index event ]Descriptive statistics will be calculated for this outcome measure using frequency tables (n, mean, median, standard deviation, minimum and maximum)
- Determinants of AMP choices (i.e. patient's characteristics, hospital characteristics, coronary intervention strategies and type of coronary stents used) [ Time Frame: Baseline ]Descriptive statistics will be calculated for this outcome measure using frequency tables (n, frequency and percentage).
Original Secondary Outcome: Same as current
Information By: AstraZeneca
Dates:
Date Received: November 18, 2013
Date Started: February 2014
Date Completion:
Last Updated: November 13, 2014
Last Verified: November 2014